gesynta.se
Contact us
About company
Gesynta Pharma develops selective mPGES-1 inhibitors for microvascular diseases in chronic inflammatory conditions with the clinical candidate, GS-248, entering clinical phase development in mid 2019.
SE
Unknown
Not verified company
